Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden–High Ovarian Cancer

In a recent clinical study, Gradalis’ Vigil showed a significant survival benefit in cTMB-H/HRP ovarian cancer, supported by durable safety and long-term overall survival. These results contributed to the FDA’s RMAT designation and expedited advancement into Phase 3 development.

Frontage supported the full development and validation of the genomics-based cTMB/HRD assay, enabling robust patient stratification and helping translate biomarker strategy into clinical success.

"*" indicates required fields

Comments

This field is for validation purposes and should be left unchanged.

First Name*

Last Name*

Company*

State*